Vanguard Personalised Indexing Administration LLC grew its place in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 13.5% within the second quarter, in response to its most up-to-date 13F submitting with the Securities and Alternate Fee. The agency owned 20,711 shares of the biopharmaceutical firm’s inventory after buying a further 2,463 shares throughout the quarter. Vanguard Personalised Indexing Administration LLC’s holdings in Halozyme Therapeutics had been price $1,084,000 as of its most up-to-date SEC submitting.
Different institutional traders additionally just lately modified their holdings of the corporate. TD Asset Administration Inc lifted its place in Halozyme Therapeutics by 517.0% within the fourth quarter. TD Asset Administration Inc now owns 1,983,916 shares of the biopharmaceutical firm’s inventory price $73,326,000 after buying a further 1,662,390 shares throughout the interval. Norges Financial institution purchased a brand new place in shares of Halozyme Therapeutics throughout the 4th quarter price about $44,935,000. Epoch Funding Companions Inc. lifted its holdings in shares of Halozyme Therapeutics by 250.5% throughout the 4th quarter. Epoch Funding Companions Inc. now owns 1,163,033 shares of the biopharmaceutical firm’s inventory price $42,986,000 after buying a further 831,199 shares throughout the interval. Boston Belief Walden Corp acquired a brand new stake in shares of Halozyme Therapeutics throughout the 2nd quarter valued at about $23,211,000. Lastly, Swedbank AB purchased a brand new stake in Halozyme Therapeutics within the first quarter valued at about $13,927,000. Institutional traders and hedge funds personal 97.79% of the corporate’s inventory.
Analysts Set New Value Targets
Numerous analysis corporations have weighed in on HALO. TD Cowen lifted their worth goal on Halozyme Therapeutics from $59.00 to $65.00 and gave the corporate a “purchase” ranking in a report on Wednesday, August seventh. Wells Fargo & Firm elevated their worth goal on Halozyme Therapeutics from $48.00 to $58.00 and gave the inventory an “chubby” ranking in a analysis be aware on Friday, June seventh. Morgan Stanley boosted their goal worth on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the corporate an “chubby” ranking in a analysis be aware on Wednesday, August seventh. Piper Sandler reduce shares of Halozyme Therapeutics from an “chubby” ranking to a “impartial” ranking and elevated their goal worth for the inventory from $48.00 to $51.00 in a analysis report on Friday, June seventh. Lastly, JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “chubby” ranking to a “impartial” ranking and boosted their worth goal for the corporate from $52.00 to $57.00 in a analysis report on Thursday, September nineteenth. Three analysis analysts have rated the inventory with a maintain ranking and 7 have issued a purchase ranking to the corporate. In line with MarketBeat, the inventory has a consensus ranking of “Reasonable Purchase” and a consensus goal worth of $60.00.
Test Out Our Newest Evaluation on HALO
Halozyme Therapeutics Value Efficiency
Shares of HALO inventory opened at $58.53 on Tuesday. Halozyme Therapeutics, Inc. has a 1 12 months low of $32.83 and a 1 12 months excessive of $65.53. The corporate has a present ratio of seven.41, a fast ratio of 6.21 and a debt-to-equity ratio of 5.19. The agency’s 50 day transferring common is $58.52 and its 200-day transferring common is $49.37. The agency has a market capitalization of $7.45 billion, a price-to-earnings ratio of 24.19, a PEG ratio of 0.57 and a beta of 1.28.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) final posted its quarterly earnings knowledge on Tuesday, August sixth. The biopharmaceutical firm reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.18. The agency had income of $231.40 million for the quarter, in comparison with the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on fairness of 195.80% and a web margin of 38.62%. The enterprise’s income for the quarter was up 4.7% in comparison with the identical quarter final 12 months. Throughout the identical quarter within the prior 12 months, the enterprise earned $0.68 EPS. Promote-side analysts forecast that Halozyme Therapeutics, Inc. will publish 3.7 EPS for the present fiscal 12 months.
Insider Shopping for and Promoting
In different Halozyme Therapeutics information, CFO Nicole Labrosse bought 5,000 shares of the corporate’s inventory in a transaction dated Monday, July twenty second. The shares had been bought at a median worth of $53.93, for a complete transaction of $269,650.00. Following the transaction, the chief monetary officer now straight owns 15,480 shares within the firm, valued at roughly $834,836.40. The transaction was disclosed in a submitting with the SEC, which is accessible by way of the SEC web site. In different Halozyme Therapeutics information, CFO Nicole Labrosse bought 5,000 shares of the corporate’s inventory in a transaction on Monday, July twenty second. The shares had been bought at a median worth of $53.93, for a complete transaction of $269,650.00. Following the completion of the sale, the chief monetary officer now owns 15,480 shares within the firm, valued at roughly $834,836.40. The sale was disclosed in a submitting with the Securities & Alternate Fee, which is accessible by way of this hyperlink. Additionally, SVP Michael J. Labarre bought 10,000 shares of the agency’s inventory in a transaction on Wednesday, September 18th. The inventory was bought at a median worth of $62.03, for a complete worth of $620,300.00. Following the completion of the transaction, the senior vp now owns 173,756 shares within the firm, valued at $10,778,084.68. The disclosure for this sale may be discovered right here. Insiders bought a complete of 84,881 shares of firm inventory price $4,888,184 during the last three months. 2.40% of the inventory is at the moment owned by firm insiders.
Halozyme Therapeutics Firm Profile
Halozyme Therapeutics, Inc, a biopharma expertise platform firm, researches, develops, and commercializes proprietary enzymes and units in the USA, Switzerland, Belgium, Japan, and internationally. The corporate’s merchandise are based mostly on the patented recombinant human hyaluronidase enzyme (rHuPH20) that allows supply of injectable biologics, comparable to monoclonal antibodies and different therapeutic molecules, in addition to small molecules and fluids.
Featured Tales
Need to see what different hedge funds are holding HALO? Go to HoldingsChannel.com to get the newest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report).
Obtain Information & Scores for Halozyme Therapeutics Every day – Enter your e mail tackle beneath to obtain a concise day by day abstract of the newest information and analysts’ scores for Halozyme Therapeutics and associated corporations with MarketBeat.com’s FREE day by day e mail e-newsletter.
